N-[(3-methylthiophen-2-yl)methyl]ethanamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[(3-methylthiophen-2-yl)methyl]ethanamine
• 化学式: C₈H₁₃NS
• mdl: MFCD04539536
• 分子量: 155.26
• InChiKey: DMIZFUZYSJLQFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Crf Receptor Antagonists and Methods
  申请人：Luo Zhiyong

  公开号：US20070293511A1

  公开（公告）日：2007-12-20

  CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , Y, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了具有治疗多种疾病的用途的CRF受体拮抗剂，包括治疗在恒温动物中表现为CRF过度分泌的疾病，如中风。本发明的CRF受体拮抗剂具有以下结构：包括立体异构体、前药和药学上可接受的盐，其中R1、R2、R3、Y、Ar和Het的定义如本文所述。还揭示了含有CRF受体拮抗剂和药学上可接受的载体的组合物，以及使用它们的方法。
• RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：EP3770148A1

  公开（公告）日：2021-01-27

  The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.

  本发明公开了一种式（I）的受体抑制剂、由其组成的药物组合物及其用途。
• Quinoline compound, preparation method and medical use therefor
  申请人：ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD.

  公开号：US10800741B2

  公开（公告）日：2020-10-13

  The present invention relates to a quinoline compound, as well as a preparation method and medical use therefor. Specifically, the present invention relates to a novel quinolone compound represented by the general formula (I) and a method for preparing the same, as well as a use therefor as an inhibitor for a plurality of protein kinases, and a use in the prevention and/or treatment of cancer in particular; the definition of each group in the general formula (I) is the same as the definition in the description.

  本发明涉及一种喹啉化合物及其制备方法和医疗用途。具体地说，本发明涉及一种通式（I）表示的新型喹啉酮化合物及其制备方法，以及其作为多种蛋白激酶抑制剂的用途，特别是在预防和/或治疗癌症方面的用途；通式（I）中各基团的定义与描述中的定义相同。
• [EN] RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF<br/>[FR] INHIBITEUR DE RÉCEPTEUR, COMPOSITION PHARMACEUTIQUE LE COMPRENANT ET SON UTILISATION<br/>[ZH] 受体抑制剂、包含其的药物组合物及其用途
  申请人：BEIJING TIDE PHARMACEUTICAL CO LTD

  公开号：WO2019179515A1

  公开（公告）日：2019-09-26

  式(I)的受体抑制剂、包含其的药物组合物及其用途。